Mylan’s Chief Commercial Officer Tony Mauro commented, “We look forward to continuing our reimbursement discussions with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Pan-Canadian Pharmaceutical Alliance (PCPA) to ensure that patients have access to Ogivri.”
The data submitted by the companies
demonstrated that Ogivri is highly similar to Herceptin, with no clinically meaningful differences in terms of efficacy, safety, purity and potency. Biocon and Mylan’s trastuzumab biosimilar is currently approved in more than 65 countries around the world, including the US.
The US Food and Drug Administration (FDA) approved Ogivri, the first biosimilar of Trastuzumab in December, 2017 for the treatment of HER2-Positive breast and gastric cancers.
and Biocon are exclusive partners on a broad portfolio of biosimilar and insulin products. Ogivri is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace.
Mylan has exclusive commercialisation rights for the product in the US, Canada, Japan, Australia, New Zealand and in the European Union and European Free Trade Association countries. Biocon has co-exclusive commercialisation rights for the product in the rest of the world.
The partnership has launched Fulphila, biosimilar of pegfilgrastim used for the treatment of patients undergoing chemotherapy, in US which has contributed significantly to the biologics business performance of Biocon in FY19. The partnership has also launched Semglee, a biosimilar insulin glargine and Ogivri in Europe.
Analyst from Ashika Institutional Research in a recent report has said that it is expected that Ogivri can generate $118mn revenue in FY21E and $125mn in FY22E for Biocon.